Polymers in Medicine

Polim. Med.
Index Copernicus (ICV 2022) – 121.55
MEiN – 70
Average rejection rate – 39.13%
ISSN 0370-0747 (print)
ISSN 2451-2699 (online) 
Periodicity – biannual

Download PDF

Polymers in Medicine

2009, vol. 39, nr 1, January-March, p. 31–45

Publication type: review article

Language: Polish

Skrobia i jej pochodne jako substancje pomocnicze w technologii doustnej i parenteralnej postaci produktu farmaceutycznego

Starch and its derivatives as excipients in oral and parenteral drug form technology

Marian Mikołaj Zgoda1,, Michał Krzysztof Kołodziejczyk1,, Michał Jakub Nachajski1,

1 Zakład Technologii Postaci Leku, Katedra Farmacji Stosowanej Uniwersytetu Medycznego w Łodzi

Streszczenie

Omówiono właściwości morfologiczne i strukturalne podstawowych rodzajów skrobi, stosowanej jako substancje pomocnicze w technologii stałych doustnych postaci leku, ze szczególnym uwzględnieniem jej właściwości bioadhezyjnych przy pełnej biodegradowalności polimeru. Podano sposób otrzymania i właściwości aplikacyjne: karboksymetyloskrobi (CMS), skrobi preżelowanej, hydroksyetyloskrobi (HES), hydroksypropyloskrobi (HPS), oraz udział skrobi chemicznie modyfikowanej w technologii wybranych produktów żywnościowych. Szczególną uwagę poświęcono hydroksyetyloskrobi (HES), która jest wykorzystywana nie tylko do produkcji płynów krwioi osoczozastępczych, lecz także jako kryptand w maskowaniu środków dopingujących. W opracowaniu monograficznym zaprezentowano w oparciu o dostępne dane z piśmiennictwa, współcześnie wykorzystywane rodzaje skrobi i produkty jej chemicznych modyfikacji, w szeroko rozumianej technologii postaci leku i produktów żywnościowych.

Abstract

The morphological and structural properties of basic types of starch used as excipients in solid drug form technology with reference to its bioadhesive properties with fully polymer biodegradation. The production technology and application of: carboxymethyl starch (CMS), pregelled starch, hydroxyethyl starch (HES), hydroxypropyl starch (HPS) and the share of modified starchin technology o f selected food products is provided. The authors focus on hydroxyethyl starch, which is used not only as bloocl and plasma substitution but also as drug camouflage agent in sports competition. In papers were presented based on literature data actually used types of starch and their chemical modifications products in drug forms and food technology.

Słowa kluczowe

naturalne polimery, skrobia, karboksymetyloskrobia (CMS), preżelowana skrobia, hydroksyetyloskrobia (HES), hydroksypropyloskrobia (HPS)

Key words

natural polymers, starch, Carboxymethyl starch (CMS), Pregelled starch, Hydroxyethyl starch (HES), Hydroxypropyl starch (HPS)

References (86)

  1. ZGODA M.M., NACHAJSKI M.J., KOŁODZIEJCZYK M.K.: Celuloza mikrokrystaliczna i jej granulometryczno-morfologiczne modyfikacje jako efektywne substancje pomocnicze w technologii tabletkowania środków leczniczych o ustalonej strukturze krystalograficznej, a także suchych mianowanych ekstraktów roślinnych. Polim. Med. (2009), 39, l, 17-30.
  2. BERRY H., RIDOUT C.W.: The preparation of compressed tablets. Port III. A study ofthe value o f po tato starch and alginic acid as disintegrating agents. J. Pharm. Pharmacol., (1950), Vol. 2, 10, 619-629.
  3. NOGAMI H., NOGAL T., FUKUOKA E., SONORE T.: Disintegration of the aspirin tablets containing potato starch and microcrystalline cellulose in various concentrations. Chem. Pharm. Bull. (1969), Vol. 17, 7, 1450-1455.
  4. KALA H., HONERBEIN B., CHWOJKA E., MOLDENHADER H.: Comparative study o f po tato starch as an additive in tablet manufacture. Die Pharmazie. (1973), Vol. 28, 11, 785-789.
  5. AMBANDH M.Y., PARIS J., MANGENOT O., PURSIEUX F., DUCHENE D.: Tablets. XII. Influence of the nature of certain adjuvants on the qualities of grains and tablets of sulfanilamide. Study of paired diluants: popato starch-tricalcium phosphate. J. Pharm. Belg. (1974), Vol. 29, 6, 523- -538.
  6. AMBANDH M.Y., MILLET J., TERRIER J.L., PURSEUX F., DUCHENE D.: Tablets. XIII. Influence of the nature of certein adjuvants an the qualities of grains and tablets of sulfanilamide. Study of paired dilwants: popoto starch-monocolcium phasphata, potato starch-dicalcium phosphate. J. Pharm. Belg. (1974), Vol. 29, 6, 539-559.
  7. BOLHUIS G.K., SMALLENBROEKA.J., LERK C.F.: Interaction of tablet disintegrants and magnesium stearate during mixing I: Effect on tablet disintegration. J. Pharm. Sci. (1981), Vol. 70, 12) 1328-1330
  8. SAWAYANAGI Y., NAMBU N., NAGAI T.: Directly compressed tablets containing chitin on c hitasan in addition to lactose on potato starch. Chem. Pharm. Bull. (1982), Vol. 30, 8, 2935-2940.
  9. KAMP H.V., BOLHUIS G.K., LERK C.F.: Improvement by super disintegrants o f the properties o f tablets containing lactose prepared by wet granulation. Pharm. Weekbl. Sci. (1983), Vol. 5, 4, 165-171.
  10. PARONEN P., JUSLIN M.: Compressional characteristics of four starches. J. Pharm. Pharmacol. (1983), Vol. 35, 10, 627-635.
  11. VOIGT R., THOMAS G.: Effect of adjuvants on the pharmaceutical and biological availability of chlorpromazine hydrochloride. Die Pharmazie. (1983), Vol. 38, 11, 736-739.
  12. WENZEL U., KALA H.: The effect of dehydration lass of tablet excipients on the energy-distance diagram and on tablet characteristics. Die Pharmazie. (1984), Vol. 39, 12, 819-821.
  13. VOIGT R., THOMAS G., GOTTE M.: The increase in the liberation rate o f propyphenazone from preoral solid dosage forms. Die Pharmazie. (1985), Vol. 40, l, 3-44.
  14. BOS C.E., BOLHURS G.K., VAN DOORNE H., LERK C.F.: Native starchin tablet formulations: properties on compaction. Pharm. Weekbl. Sci. (1987), Vol. 9, 5, 274-282.
  15. HENNIG D., SCHUBERT E.: The effect ofselected disintegrants on the properties of three hydrochlorothizide tablet formulations. Die Pharmazie (1987), Vol. 42, 11, 725-728.
  16. GEBE-MARIAM T., NRKOLAYEV A.S.: Evolution of starch obtained from Ensete ventricosum as a binder and disintegrant of compressed tablets. J. Pharm. Pharmocol. (1993), Vol. 45, 4, 317- -320.
  17. OTSUKA M., MOURU Y., MATSUDA Y.: Chemometric evaluation of pharmaceutical properties of antipyrine granules by near-infrared spectroscopy. AAPS Pharm. Sci Tech. (2003), Vol. 4, 3, E47.
  18. TARVAINEN M., PELTONEN S., MIKKONEN H., ELOVAARA M., TUUNAINEN M. et all.: Aqueus starch acetate dispersion as a novel coating materiał for controlled release products. J. Controll. Release. (2004), Vol. 96, l, 179-192.
  19. SCHINZINGER O., SCHMIDT P.: Comparison ofthe granulation behavior of three different excipients in a laboratary fluidized bed granulator us ing statistical method. Pharmaceutical Develop. Technology. (2005), Vol. 10, 2, 175-188.
  20. OTSUKA M.: Chemoinformetical evolution of granule and tablet properties of pharmaceutical preparations by near-infrered spectroscopy. Chemometrics Intell. Lab. Systems. (2006), Vol. 82, 112, 109-114.
  21. TANABE H., OTSUKA K., OTSUKA M.: Theoretical analysis o f tablet hardness prediction using chemoinformetric near-infrared spectroscopy. Int. J. Japan Soc. Anal. Chem (Anal. Sci), (2007), Vol. 23, 7, 857-862.
  22. MASSIMO G., SANTI P., COLOMBO G., NICOU S., ZANI F., KOLOMBO P., BETTING R.: The suitability of disintegrating force kinetics for studying the effect o f manufacturing parameters on spironoloctone tablet properties. AAPS Pharm. Sci Tech. (2003), Vol. 4, 2, E 17.
  23. ANTIKAINEN O., YLIRUUSI J.: Determining the compression beheviour o f pharmaceutical powders from the force distonce compression profile. Int. J. Pharmaceutics. (2003), Vol. 252, 112, 253-261.
  24. HOUSCHILD K., PICKER-FREYER K.M.: Evolution of a new coprocessed compound based on lactose and maize sterch for tablet formulation. AAPS. Pharm., Sci. (2004), Vol. 6, 2, E 16.
  25. MAREIRA-ALTAIR B., DIAS-IARA L.T., NETO-GRACILIANO O., ZAGATTO EUOS A.G., KUBATA LAURA T.: Solid-phase fluorescence spectroscopy for the determination o f acetylsalicylic acid in pawdered pharmaceutical samples. Analy. Chernica Acta. (2004), Vol523, l, 49-52.
  26. WEYENBERG W., VERMEIRE A., V ANDERVOORT J., REMON J.P., LUDWIG A.: Effects of ro11er compaction settings on the preparation of bioadhesive ranules and ocular minitablets. Europ. J. Pharm. Biopharm. (2005), Vol. 59, 3, 527- -536.
  27. KRANZ H., BRUN V. LE., WAGNER T.: Development of a multi particulate extended release formulation for ZK 811 752, a weakly basie drug. Int. J. Pharm. (2005), Vol. 299, 112, 84-91.
  28. KRANZ H., WAGNER T.: Effects of formulation and process variabies on the release o f a weakly basie drug from single unit extended release formulations. Europ. J. Pharm. Biopharm. (2006), Vol, 62, l , 70-76.
  29. KIMDRA G., PUCHKOV M., BETZ G., LEWENBERGER H.: Percolation theory and the role ofmaize strach as a disintegrant for a low water-soluhle drug. Pharm. Dev. Technol. (2007), Vol. 12, l, 11-19.
  30. CHEN L., LI X., PANG Y., LI L., ZHANG X., Yu L.: Resistant starch as a carrier for oral colontargeting drug matrix system. J. mater. Sci. mater. Med. (2007), Vol. 18, 11, 2199-2203.
  31. KIMURA G., BETZ G., LEUENBERGER H.: Influence of loading volume of mefenamic acid on granules and tablet characteristic using a compaction simulator.Pharm. Develop. Technology. (2007), Vol. 12, 6, 627-635.
  32. FRANKLIN-UDE P., EMEJE M.O., OFOEFULE S.I.: Evoluation of Geelan Gum as a ulating agent for Chloroguine phosphate tablets. J. Pharmacol. Toxicology. (2008), Vol. 3, 2) 53-63.
  33. LIMWONG V., SUTANTHAVIBUL N., KULVANICH P.: Spherical composite particiers o f rice starch and microcrysta11ine ce11ulose: a new coprocessed excipient for direct compression. AAPS Pharm. Sci. Tech. (2004), Vol. 5, 2, E 30.
  34. KITTIPONGPATANA O.S.: Physicochemical and Pharmaceutical properties of carboxymethyl rice starches modified from native starches with different amylase eontent Cereal Chemistry. (2007), Vol. 84, 4, 331-336.
  35. JONTSCHER C., WELIKOWA E.: Optimization ofthe composition of a multicomponent drug form by mathematical investigational desingning an experimental testing. Pharmazie. (1981), Vol. 36, l, 32-34.
  36. ANJUM F.M., WALKER C.E.: Review on the significance of starch and protein to wheat kemel hardness. J. Sci. Food and Agriculture. (1991), Vol. 51, l, 1-13.
  37. SRIROMANI P.K., CLAIR J.: Statistical comparisan of high shear versus low-shear granulation using a common formulation. Drug Dev. Ind. Pharm. (2000), 26, 357-364.
  38. CARR R.L.: Particie behaviour storage and flow. Br. Chem. Eng. (1970), 15, 1541-1549
  39. CALLAHAN J.C., CLEARY G.W., ELEFANT M.: Equilibrium moisture eontent of pharmaceutical excipients.Drug Dev. Ind. Pharm. (1982), 8, 355-369.
  40. CARR R.L.: Particie behaviour storage and flow. Br. Chem. Eng. (1970), 15, 1541-1549.
  41. KELSEY J.C.: Sterelization of glove powder by autociaving. Mon. Bull. Minist. Health (1962), 21, 17-21.
  42. NEELY J., DAVIS I.D.: Starch granulomatosis of the peritoneum. Br. Med. J. (1971), 3, 625-629.
  43. MICHAELS L., SHAH N.S.: Dangers of com starch powder [letter]. Br. Med. J. (1973), 2, 714.
  44. KARCIOGLU Z.A., ARAN A.J., HOLMES D.L.: Inflammation due to surgical glove powders in the robbit eye. Arch. Ophthalmol. (1988), l06, 6, 808-811.
  45. RUHL C.M., URBANCIC J.H., FORESMAN P.A.: A new hazard of comstarch, an absarbale dusting powder. J. Emerg. Med. (1994), 12, l, 11-14.
  46. COTE S.J., FISHER M.D., KHEIR J.N: Ease of donning commercially available latex examination gloves. J. Biomed. Mater. Res. (1998), 43, 3, 331-337.
  47. TRUSCOTT W.: Post-surgical complications associated with the use of USP. Surg Technol. Int. (2000), VIII, 65-73.
  48. SMALL L.E., AUGSBURGER L.L.: Aspects of the lubrication requirements for an automatic capsule filling machine. Drug. Dev. Ind. Pharm. (1978), 4, 345-372.
  49. MATTSON S., NYSTROM C.: Evaluation of critical binder properties affecting the compactabili ty o f binary mixtures. Drug Dev. Ind. Pharm. (200 l), 27, 181-194.
  50. RUMC E.M., RHOOES C.T., WELCH S., BERNARDO P.: Evaluations o f the mechanism o f a disintegrant action. Drug Dev. Ind. Pharm. (1982), 8, 87-109.
  51. MANUOHANE K.S., CONTRCTOR A.M., KIM H.Y., SHANGRAW R.F.: Tableting properties of a directly compressible starch. J. Pharm. Sci (1969), 58, 616-620.
  52. UNDERWOOD T.W., CADWALLADER D.E.: Influence of various starches on dissolution rate of salicylic acid from tablets. J. Pharm. Sci (1972), 61, 239-243.
  53. BOLHUIS G.K., LERK C.F.: Comparative evaluation of excipients for direct compression. Pharm. Weekbl. (1973), 108, 469-481.
  54. SAKR A.M., ELSABBAGH H.M., EMARA K.M.: Sta-Rx 1500 starch: a new vehicle for the direct compression of tablets. Arch. Pharm. Chem. (Sci). (1974), 2, 14-24.
  55. ScHWARTZ J.B., MARTIN E.T., DEHNER E.J.: Intragranulator starch: comparison of starch USP and modified comstarch. J. Pharm. Sci (1975), 64, 328-332.
  56. SHANGRAW R.F., WALLACE J.W., BOWERS F.M.: Morphology and functionality in tablet excipients for direct compression: port II. Pharm. Technol. (1981), 5, 10, 44-60.
  57. CHILAMKURTI R.W., RHODES C.T., SCHWARTZ J.B.: Same studies on compression properties o f tablet matrices using a computerized instrumental press. Drug. Dev. Ind. Phann. (1982), 8, 63-86.
  58. MALAMATARIS S., GomAs P., DIMITRIOU A.: Moisture sorption and tensile strength of same tableted direct compression excipients. In. J. Phann. (1991), 68, 51-60.
  59. ISKANDARANI B., SHIROMANI P.K., CLAIR J.H.: Scale - up feasibility in high - shear mixers: determination through statistical procedures. Drug. Dev. Ind. Pharm. (2001), 27, 651-657.
  60. JAIYEOBA K.T., SPRING M.S.: The granulation o f ternary mixtures: the effect o f the stability o f the excipients. J. Pharm. Pharmacol. (1980), 32, 1-5.
  61. WURSTER D.E., PECK G.E., KRLDSIG D.O.: A comparison o f the moisture adsorptiondesorption properties of com starch USP, and directly compressible starch. Drug. Dev. Ind. Pharm. (1982), 8, 343-354.
  62. ALEBIOWU G., ITIOLA O.A.: Compression characteristics o f native nad pregelatinized forms o f sorghum, plantain, and com starches, and the mechanical properties of their tablets. Drug. Dev. Ind. Pharm. (2002), 28, 6, 663-672.
  63. MADJDPOU., DETTORI N., FRASCAROLO P., BURSKI M., BOLL M., FISCH A., BOMBELI T., SPAHAN D.R.: Molecular weight ofhydroxyethyl starch: is there an effect on blood coagulation and pharmacokinetics? British Joumal of Anaesthesia (2005), 94, 5, 569-576.
  64. JANICKI M., ZOLLINGERA., SEIFER B., POPOVIC D., PASCH T., SPAHN D.R: Comprromised blood coagulation: an vitro comparison o f hydroxyethyl starch 130/0. 4 and hydroxyethyl starch 200/0.5 using thrombelastography. Anaesth. Analg. (1998), Vol. 87, 989-993.
  65. LEHMANN, G. et al.: Bioequivalence Comparison between HES 130/0. 42/6: l. (Venofudin) and HES 130/0. 4/9: l (Voluven). Drugs R D (2007), 8, 4 229-240.
  66. BOLDT J., HAISCH G., SUITNER S., KUMLE B., ScHELLHAAS A.: Effects of a new modifed, balanced hydroxyethyl starch preparation (Hextenda) on measuresof coagulation. British Joumal of Anaesthesia (2002), 89, 5, 722-728.
  67. TREM J. et al.: Intensive care Med. (1999), 258- 268.
  68. LANGERON O. et al.: Anesth. Analg. (2001) 91 , p. 855-862
  69. STRAUS R.G. et. Al.: Transfusion (1986), 257- 260.
  70. JAMNICKI M. i in.: Anesthesiology (2000), 1231- 1237.
  71. PRERANA P., SHROFF, SADANAND KULKARNI, SMITA LELE, SUREKHA KAMATH, LATHA CHAUDHARI, L.V.: Dewoolkar Randomized, Comparative Study between Polygeline nd Hydroxyethyl Starch (130/0.4). As Volume Preload before Spinał Anaesthesia J. Anesth. Clin. Pharmacology (2007); 23, 3, 269-272.
  72. JUNGHEINRICH C., SCHARPF R., W ARGENAU M., BEPPERLING F., FRANCOIS J., BARON: The Pharmacokinetics and T olerability o fan Intravenous Infusion ofthe New Hydroxyethyl Starch 130/0.4 (6%, 500mL) in Mild-to-Severe Renal impairment Anesth. Analg. (2002), 95, 544-551
  73. MNTLMEIER T., VOLMAR B., MENGER M.D., SCHEWIOR L., RASCHE M., SERASER K.D.: Small volume hypertonic hydroxyethyl starch reduces acute Microvascular dysfunction after closed soft-tissue trauma. The Journal of Bone and Joint Surgery (2003) January,Vol. 85-B, l.
  74. STUART S., KAPLAN, MD. T. S. PARK, MD., ERNESTO R. GONZALES B. S. N., JEFFREY M., GRODAY.: Hydroxyethyl Starch Reduces Leukocyte Adherence and Vascular Injury in the Newbom Pig Cerebral CirculationAfter Asphyxia Stroke. (2000), 31,2218-2223
  75. STANDL T., BURMERSTER M., SCHROEDER F., CURRLIN E., SCHULTE AM ESER J., FREITAG M, SCHULTE AM ESCH J.: Hydroxyethyl Starch (HES) 130/0.4Provides Larger and Faster Increases in Tissue Oxygen Tension in Comparison with Prehemodilution Values the HES 70/0.5 or HES 200/0.5 in Volunteers Undergoing Acute Normovolemic Hemodilution. Anesth. Analg. (2003), 96, 936-943.
  76. Światowy Kodeks Antydopingowy Lista zakazanych Substancji I Metod 2007 Lista Zabroniona2007.
  77. METZE D., REIMANN D., SZEPFALUSR Z., BOHLE B., KRAFT D., LUGER T.A.: Persistent pruritusafter hydroxyethyl starch infusion therapy: a result of long-term storage in cutaneous nerves. British Journal of Dermatology Vol. 136, Issue 4 April (1997), 553-559
  78. WARREN B.B., DURIEUX M.E.: Hydroxyethyl starch: safe or not? Anesth. Analg. (1997), 84, 206-212.
  79. VOM N.H., BOTHNER U., LERCH G., LINDNER K.H., GEORGIEFF M.: Largedose administration of 6% hydroxyethyl starch 200/0.5 total hip arthroplasty: plasma homeostasis, and renal function compared to use o f 5% human albumin. Anesth. Analg. (1996), 83, 262-268.
  80. GONI I., FERRERO M.C., JIMENEZ-CASTELLANOS R.M., GURRUCHAGA M.: Synthesis ofhydroxypropyl methacrylate/polysaccharide graft copolymers as matrices for controlled release tablets. Drug Dev. Ind. Pharm. (2002), 28, 9, 1101-1115.
  81. FERRERO M.C., VEASCO M.V, MVNOZ A. et al.: Drug release from a famiły of graft copolymers of metbył methacrylate. Int. J. Pharm. (1997), 149, 133-240.
  82. Japan Pharmaceutical Excipients Council. Japanese Pharmaceutical Excipients 2004. Tokyo, Yakuji Nippo. (2004), 425-427.
  83. VRSAVARUNGRAJ N., REMON J.P.: An evaluation of hydroxypropyl starch as disintegrant and binder in tablet formulation. Drug Dev Ind Pharm 1991; 17 (10): 1389-1396.
  84. VENACRO A., TEIXEIRA J.A., MOTA M.: Evaluation of crude hydroxypropyl starch as a bioseparation aqueous-phase-forming polimer. Biotechnol. Prog. (1993), 9, 6, 635-639.
  85. KRYSIŃSKA P., FORTUNA T.: Rola skrobi modyfikowanych w wybranych produktach typu
  86. GRAEDON J., GRAEDON T.: The People Guide to deadly drug interactions 1995 by raedon Enterprises, Inc. St. Martin 's Press, New York, USA.
© Wroclaw Medical University